Biology:Adenosine A2B receptor

From HandWiki
Short description: Protein-coding gene in the species Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example

The adenosine A2B receptor, also known as ADORA2B, is a G-protein coupled adenosine receptor, and also denotes the human adenosine A2b receptor gene which encodes it.[1]

Mechanism

This integral membrane protein stimulates adenylate cyclase activity in the presence of adenosine. This protein also interacts with netrin-1, which is involved in axon elongation.

Gene

The gene is located near the Smith-Magenis syndrome region on chromosome 17.[1]

Ligands

Research into selective A2B ligands has lagged somewhat behind the development of ligands for the other three adenosine receptor subtypes, but a number of A2B-selective compounds have now been developed,[2][3][4][5][6][7][8][9][10][11] and research into their potential therapeutic applications is ongoing.[12][13][14][15][16][17][18]

Agonists

  • BAY 60-6583
  • NECA (N-ethylcarboxamidoadenosine)
  • (S)-PHPNECA - high affinity and efficacy at A2B, but poor selectivity over other adenosine receptor subtypes
  • LUF-5835
  • LUF-5845 - partial agonist

Antagonists and inverse agonists

  • Compound 38:[19] antagonist, high affinity and good subtype selectivity
  • ISAM-R56A:[18] non-xanthinic high affinity selective antagonist (Ki: 1.50 nM)
  • ISAM-140:[20] non-xanthinic selective antagonist (Ki: 3.49 nM).
  • ATL-801
  • CVT-6883
  • MRS-1706
  • MRS-1754
  • OSIP-339,391
  • PSB-603: xanthinic antagonist
  • PSB-0788: xanthinic antagonist
  • PSB-1115: xanthinic antagonist
  • PSB-1901:[21] xanthinic antagonist with picomolar potency

References

  1. 1.0 1.1 "Entrez Gene: ADORA2B adenosine A2b receptor". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=136. 
  2. "N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands". Journal of Medicinal Chemistry 45 (15): 3271–3279. July 2002. doi:10.1021/jm0109762. PMID 12109910. 
  3. "Purine nucleosides bearing 1-alkynyl chains as adenosine receptor agonists". Current Pharmaceutical Design 8 (26): 2285–2298. 2002. doi:10.2174/1381612023392856. PMID 12369946. http://www.bentham-direct.org/pages/content.php?CPD/2002/00000008/00000026/0002B.SGM. 
  4. "Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists". Journal of Medicinal Chemistry 47 (6): 1434–1447. March 2004. doi:10.1021/jm0309654. PMID 14998332. 
  5. "A2B adenosine receptor antagonists: recent developments". Mini Reviews in Medicinal Chemistry 5 (12): 1053–1060. December 2005. doi:10.2174/138955705774933374. PMID 16375751. http://www.bentham-direct.org/pages/content.php?MRMC/2005/00000005/00000012/0001N.SGM. 
  6. "Ligands for A2B adenosine receptor subtype". Current Medicinal Chemistry 13 (28): 3467–3482. 2006. doi:10.2174/092986706779010306. PMID 17168717. http://www.bentham-direct.org/pages/content.php?CMC/2006/00000013/00000028/0008C.SGM. 
  7. "Structure-affinity relationships of adenosine A2B receptor ligands". Medicinal Research Reviews 26 (5): 667–698. September 2006. doi:10.1002/med.20069. PMID 16847822. 
  8. "Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists". Bioorganic & Medicinal Chemistry Letters 16 (2): 302–306. January 2006. doi:10.1016/j.bmcl.2005.10.002. PMID 16275090. 
  9. "Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor". Journal of Medicinal Chemistry 49 (1): 282–299. January 2006. doi:10.1021/jm0506221. PMID 16392813. 
  10. "1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists". Bioorganic & Medicinal Chemistry 16 (5): 2419–2430. March 2008. doi:10.1016/j.bmc.2007.11.058. PMID 18077171. 
  11. "1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor". Bioorganic & Medicinal Chemistry 16 (6): 2852–2869. March 2008. doi:10.1016/j.bmc.2008.01.002. PMID 18226909. 
  12. "Medicinal chemistry and pharmacology of A2B adenosine receptors". Current Topics in Medicinal Chemistry 3 (4): 427–443. 2003. doi:10.2174/1568026033392264. PMID 12570760. http://www.bentham-direct.org/pages/content.php?CTMC/2003/00000003/00000004/0007R.SGM. 
  13. "Emerging adenosine receptor agonists". Expert Opinion on Emerging Drugs 12 (3): 479–492. September 2007. doi:10.1517/14728214.12.3.479. PMID 17874974. https://zenodo.org/record/1236313. 
  14. "Blockade of adenosine A2B receptors ameliorates murine colitis". British Journal of Pharmacology 155 (1): 127–137. September 2008. doi:10.1038/bjp.2008.227. PMID 18536750. 
  15. "Adenosine receptors: therapeutic aspects for inflammatory and immune diseases". Nature Reviews. Drug Discovery 7 (9): 759–770. September 2008. doi:10.1038/nrd2638. PMID 18758473. 
  16. "The adenosine a2b receptor: its role in inflammation". Endocrine, Metabolic & Immune Disorders Drug Targets 8 (4): 244–254. December 2008. doi:10.2174/187153008786848303. PMID 19075778. http://www.bentham-direct.org/pages/content.php?EMIDDT/2008/00000008/00000004/0003V.SGM. 
  17. "5'-N-ethylcarboxamide induces IL-6 expression via MAPKs and NF-kappaB activation through Akt, Ca(2+)/PKC, cAMP signaling pathways in mouse embryonic stem cells". Journal of Cellular Physiology 219 (3): 752–759. June 2009. doi:10.1002/jcp.21721. PMID 19194991. 
  18. 18.0 18.1 "A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models". Journal for Immunotherapy of Cancer 10 (5): e004592. May 2022. doi:10.1136/jitc-2022-004592. PMID 35580926. 
  19. "1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships". Bioorganic & Medicinal Chemistry 16 (22): 9780–9789. November 2008. doi:10.1016/j.bmc.2008.09.067. PMID 18938084. 
  20. "Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes". Journal of Medicinal Chemistry 59 (5): 1967–1983. March 2016. doi:10.1021/acs.jmedchem.5b01586. PMID 26824742. 
  21. "A2B Adenosine Receptor Antagonists with Picomolar Potency". Journal of Medicinal Chemistry 62 (8): 4032–4055. April 2019. doi:10.1021/acs.jmedchem.9b00071. PMID 30835463. 

Further reading

External links